Infliximab vs adalimumab
Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes loss of clinical response (at 56 weeks, less than 100 points in CDAI… compared with adalimumab (very low certainty).
1 finding from 1 review
- Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes onlyRR 0.68 [0.29, 1.59]1 study · 73 participantsVery low